Orchid Pharma shares rose by 3.94%, trading at ₹1,509.90 on the NSE as of 11:29 am, driven by impressive Q2 FY25 financial results showcasing robust growth in revenue and profitability.
Key Financial Highlights (Q2 FY25 vs Q2 FY24):
- Revenue from Operations: ₹222.7 crore, up 12% from ₹198.8 crore.
- EBITDA: ₹37.5 crore, a 20% increase with an improved EBITDA margin of 17%.
- Profit Before Tax (PBT): ₹25.6 crore, marking a 26% growth.
- Net Profit (PAT): ₹25.6 crore, also up 26%.
Half-Year Performance (6M FY25):
- Revenue: ₹467.1 crore, reflecting a 22% YoY growth.
- EBITDA: ₹78.6 crore, up 44%.
- PAT: ₹54.7 crore, achieving a 76% YoY increase.
Orchid Pharma’s strong Q2 and half-yearly performance highlights the company’s effective cost management and operational efficiencies, boosting investor confidence and contributing to the stock’s upward momentum on the exchange.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
